EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Effectiveness of mogamulizumab in patients with Mycosis Fungoides or Sézary syndrome: A multicentre, retrospective, real‐world French study

M Beylot-Barry iD, G Quereux, C Nardin, A-B Duval-Modeste, O Dereure iD, S Dalac-Rat, G Dobos, A Pham-Ledard iD, C Ram-Wolff, M D'Incan, F Grange, V Braniste iD und 1 weitere

Journal of the European Academy of Dermatology and Venereology · 2023-09 · 37 (9) · 1777-1784

DOI: 10.1111/jdv.19134 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 13.05.2023. Verfasst von M Beylot-Barry und 12 weiteren Autor:innen. Beteiligte Einrichtung: BoRdeaux Institute of Oncology, INSERM U1312, Team 5, Bordeaux University, Bordeaux, France. Hauptthemen laut MEDLINE: Sezary Syndrome, Skin Neoplasms, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Kyowa Kirin Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Efficacy and safety of mogamulizumab, a monoclonal antibody directed against C‐C chemokine receptor 4, were demonstrated in a previous multinational clinical trial conducted in patients with previously treated cutaneous T‐cell lymphoma (CTCL): Sézary syndrome (SS) or Mycosis Fungoides (MF).

Objectives

The real‐world French OMEGA study aimed to describe effectiveness and tolerability of mogamulizumab in adult patients with CTCL, overall and according to the disease (SS or MF).

Methods

In this retrospective study, patients treated with mogamulizumab for SS or MF were included from 14 French expert centres. The overall response rate (ORR) under treatment was described (primary criterion), as well as treatment use and safety data.

Results

The 122 analysed patients (69 SS, 53 MF) were aged 66.6 ± 12.1 years at mogamulizumab initiation, and their median disease duration was 2.5 years (IQR: 1.3–5.6). Prior to treatment start, they received a median of three systemic CTCL therapies (2–5). Overall, 77.8% of patients suffered from advanced disease (Stage IIB–IVB), with frequent blood (B1/B2) involvement (67.5%). Over the treatment period (median: 4.6 months, 2.1–7.2), 96.7% of patients received all the planned mogamulizumab infusions. Among the 109 patients evaluable for effectiveness, ORR was 58.7% (95% CI [48.9–68.1]) overall, 69.5% [56.1–80.8] in SS and 46.0% [31.8–60.7] in MF. Compartmental response in the blood was observed in 81.8% [69.1–90.9] of SS patients. Skin responses were observed in 57.0% [47.0–66.5] of patients overall, 66.7% [52.9–78.6] in SS and 46.0% [31.8–60.7] in MF. The most common serious adverse drug reactions were rash (8.1% of patients) and infusion‐related reactions (2.4%) which led to treatment discontinuation in 7.3% and 0.8% of patients, respectively. One patient with SS died from mogamulizumab‐related tumour lysis syndrome.

Conclusions

This large French study confirmed the effectiveness and tolerability of mogamulizumab in SS and MF patients in routine medical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sezary SyndromeSkin NeoplasmsMycosis FungoidesLymphoma, T-Cell, CutaneousAdultHumansRetrospective StudiesAntibodies, Monoclonal, Humanized

Substanzen

mogamulizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • BoRdeaux Institute of Oncology, INSERM U1312, Team 5, Bordeaux University, Bordeaux, France.
  • Dermatology Department, CHU Bordeaux, Bordeaux, France.
  • Dermatology Department, Nantes University Hospital, University of Nantes, CIC 1413, INSERM UMR 1302/EMR6001 INCIT, Nantes, France.
  • Dermatology Department, Minjoz Hospital, CHU Besancon, Besancon, France.
  • INSERM U1098, University of Franche Comté, EFS Bourgogne Franche-Comté and Franche-Comté University, Besançon, France.
  • Department of Dermatology, INSERM U519, Rouen University Hospital, Rouen, France.

ORCID-Profile: M Beylot-Barry, O Dereure, A Pham-Ledard, V Braniste, M Bagot

Förderung

  • Kyowa Kirin Pharma

Zitieren

APA

Beylot-Barry, M., Quereux, G., Nardin, C., Duval-Modeste, A. B., Dereure, O., Dalac-Rat, S., Dobos, G., Pham-Ledard, A., Ram-Wolff, C., D'Incan, M., Grange, F., Braniste, V., & Bagot, M. (2023). Effectiveness of mogamulizumab in patients with Mycosis Fungoides or Sézary syndrome: A multicentre, retrospective, real‐world French study. Journal of the European Academy of Dermatology and Venereology, 37(9), 1777-1784. https://doi.org/10.1111/jdv.19134

Vancouver

Beylot-Barry M, Quereux G, Nardin C, Duval-Modeste AB, Dereure O, Dalac-Rat S, et al. Effectiveness of mogamulizumab in patients with Mycosis Fungoides or Sézary syndrome: A multicentre, retrospective, real‐world French study. Journal of the European Academy of Dermatology and Venereology. 2023;37(9):1777-1784. doi:10.1111/jdv.19134

BibTeX
@article{BeylotBarry2023,
  author = {Beylot-Barry, M and Quereux, G and Nardin, C and Duval-Modeste, A-B and Dereure, O and Dalac-Rat, S and Dobos, G and Pham-Ledard, A and Ram-Wolff, C and D'Incan, M and Grange, F and Braniste, V and Bagot, M},
  title = {Effectiveness of mogamulizumab in patients with Mycosis Fungoides or Sézary syndrome: A multicentre, retrospective, real‐world French study},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2023},
  volume = {37},
  number = {9},
  pages = {1777--1784},
  doi = {10.1111/jdv.19134}
}
Kostenlos starten →